Because Tubastatin A inhibits both HDAC6 and HDAC10, these hybrids would likely be HDAC6/8/10 inhibitors.6 While HDAC6 expression does not significantly correlate with prognosis in neuroblastoma,7a, 21 HDAC6 inhibitors have been found to be well tolerated in clinical studies22 and selective HDAC6 inhibition has been shown to be non‐cytotoxic in cancer settings.23 We therefore allowed HDAC6 inhibition as a feature of our compounds. The gene discussed is HDAC6; the disease is cancer.